SSS 07

Drug Profile

SSS 07

Alternative Names: anti-tumour necrosis factor monoclonal antibody - 3SBio/Apexigen; APX-001; humanised TNF alpha monoclonal antibody - 3SBio/Apexigen; SSS-07

Latest Information Update: 25 Jun 2015

Price : $50

At a glance

  • Originator Epitomics
  • Developer 3SBio
  • Class Monoclonal antibodies
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Rheumatoid arthritis
  • Preclinical Autoimmune disorders; Psoriasis

Most Recent Events

  • 22 Jun 2015 3SBio plans a phase Ib trial for Rheumatoid arthritis (In volunteers) in China
  • 22 Jun 2015 3SBio acquires global rights to SSS 07 from Apexigen
  • 01 May 2015 Phase-I clinical trials in Rheumatoid arthritis (In volunteers) in China (Parenteral) (NCT02460393)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top